Immunoglobulin epsilon (IgE)

Immunoglobulin E (IgE) is a specialized antibody isotype that plays a central role in the immune system's response to allergens and helminthic parasites. It is primarily synthesized by plasma cells, and the U266 human myeloma cell line is frequently utilized as a research model due to its ability to constitutively produce and secrete monoclonal IgE (PubMed: 4501180). IgE functions by binding to high-affinity FcεRI receptors on the surface of mast cells and basophils, sensitizing these cells to specific environmental allergens. Upon subsequent exposure to an allergen, the cross-linking of receptor-bound IgE triggers the rapid release of inflammatory mediators such as histamine, leading to type I hypersensitivity reactions (StatPearls: Type I Hypersensitivity). Pathological elevations in IgE production are associated with various allergic diseases, including asthma, allergic rhinitis, and atopic dermatitis. Therapeutic strategies targeting this pathway often involve monoclonal antibodies that neutralize free IgE or inhibit its production to prevent the allergic cascade (NCBI: Omalizumab). By reducing the amount of circulating IgE, these treatments also lead to the downregulation of FcεRI receptors on effector cells, further dampening the immune response. The study of IgE production in U266 cells remains a vital component of drug discovery efforts aimed at identifying small molecules or biologics that can modulate B-cell class switching and antibody secretion.

Other names

Immunoglobulin EIgEIGHEImmunoglobulin heavy constant epsilonepsilon heavy chain

Monoclonal antibodies bind to the C3 (CH3) domain of the IgE heavy chain, which is the site that interacts with the high-affinity FcεRI receptor. This sequestration prevents circulating IgE from docking on mast cells and basophils, thereby inhibiting the release of inflammatory mediators like histamine and leukotrienes (PubMed: 12762576).